Donepezil Hydrochloride
Product Images NDC 46708-092

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Donepezil Hydrochloride (NDC 46708-092). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

10 mg-30 Tablets In Hdpe Bottle Pack (Donepezil 10mg)

This is a medication called Donepezil Hydrochloride that comes in a film-coated tablet, with each tablet containing 10mg of the active ingredient. The instructions for dosage and use can be found in the accompanying prescribing information. It is recommended to store this medication in a tight container at a temperature of 20-25°C (68-77°F). It is manufactured by Alembic Pharmaceuticals Limited in India, with the manufacturing address and NDC number provided. The medication should only be dispensed along with the patient information sheet by a pharmacist. The lot number of the medication is not available in the text.*

FDA Label Image

5 mg-30 Tablets In Hdpe Bottle Pack (Donepezil 5mg)

Each film-coated tablet contains 5mg of donepezil hydrochloride. This medicine should be stored in tightly closed containers between 20° to 25°C (68° to 77°F). Dosage instructions can be found in the accompanying prescribing information sheet. Dispensed by pharmacists with a prescription, and a patient information sheet should be provided. The manufacturer is Alembic Pharmaceuticals Limited, and the tablets are sold in 30-tablet quantities under the NDC 46708-092-30. The medicine has been licensed under Mfg. Lic. No.: G/959. Lot and EXP information not available.*

FDA Label Image

Figure 1 (Donepezil Figure1)

FDA Label Image

Figure 10 (Donepezil Figure10)

The text appears to be a graph or chart with some numerical values and medical terminology related to patients undergoing treatment. The title of the chart is "ADCS-ADL Change from Baseline" and it shows the percentage of patients completing 6 months of double-blind treatment with particular changes from baseline in ADCS-ADL-Severe Scores. Without the graph, it is not possible to give a more accurate description of the content.*

FDA Label Image

Figure 2 (Donepezil Figure2)

FDA Label Image

Figure 3 (Donepezil Figure3)

The text is a chart showing the percentage of patients who experienced improvement, worsening, or no change in their condition at 24 weeks, as measured by the CIBIC-plus Rating. The chart is divided into categories of marked, moderate, and minimal improvement or worsening. There is no additional information available from the text.*

FDA Label Image

Figure 4 (Donepezil Figure4)

The text is a figure caption for a time-course graph showing the change in ADAS-cog score for patients completing a 15-week study on drug treatment. It is related to drug treatment for some condition.*

FDA Label Image

Figure 5 (Donepezil Figure5)

FDA Label Image

Figure 6 (Donepezil Figure6)

FDA Label Image

Figure 7 (Donepezil Figure7)

FDA Label Image

Figure 8 (Donepezil Figure8)

FDA Label Image

Figure 9 (Donepezil Figure9)

FDA Label Image

Structure (Donepezil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.